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Key points: 
This paper reports a large cross sectional study of polypharmacy and physical comorbidity among 
older people with dementia.  
People with dementia  had more physical conditions and were also prescribed more medications 
than those without dementia. 
This data highlights the importance of integrating specialist and non-specialist care to support 
complex symptom management. 
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Abstract 
Background 
The care of older people with dementia is often complicated by physical comorbidity and 
polypharmacy, but the extent and patterns of these have not been well described. This paper 
reports analysis of these factors within a large, cross sectional primary care dataset. 
Methods 
Data was extracted for 291,169 people aged 65 years or over registered with 314 general practices 
in Scotland, of whom 10,258 had an electronically recorded dementia  diagnosis. Differences in the 
number and type of 32 physical conditions, and the number of repeat prescriptions in those with 
and without dementia were examined.  Age-gender standardised rates were used to calculate odds 
ratio (ORs) of physical comorbidity and polypharmacy. 
Results 
People with dementia, after controlling for age and sex had on average more physical conditions 
than controls (mean number of conditions 2.9 vs. 2.4; p<0.001) and were on more repeat 
medication (mean number of repeats 5.4 vs. 4.2; p<0.001). Those with dementia were more likely to 
have five or more physical conditions (age-sex standardised OR [sOR] 1.42, 95% CI 1.35 to 1.50; 
p<0.001) and were also more likely to be on five or more (sOR 1.46; 95% CI 1.40 to 1.52; p<0.001) or 
ten or more repeat prescriptions (sOR 2.01; 95% CI 1.90 to 2.12; p<0.001).  
Conclusions 
People with dementia have a higher burden of co-morbid physical disease and polypharmacy than 
those without dementia, even after accounting for age and sex differences. Such complex needs 
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require an integrated response from general health professionals and multi-disciplinary dementia 
specialists. 
[249]
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Background 
Ageing populations are driving large increases in the prevalence of dementia, posing major 
challenges to healthcare systems internationally [1]. However, dementia and the healthcare of 
people living with dementia is often viewed in isolation by policymakers and healthcare providers. 
Health services are typically organised around single conditions, leading to people with multiple 
conditions often receiving uncoordinated or fragmented care. This is particularly true for people 
with physical-mental health comorbidity, since physical and mental health services in most countries 
are not well integrated [2,]. For people with dementia, older people’s mental health teams focus 
almost exclusively on mental health care, and there may be a range of physical specialists involved in 
care in addition to geriatricians and primary care physicians.  
A number of studies have reported the prevalence of co-morbidity in older people with dementia, 
but the evidence base is inconsistent due to limited sample size and selection bias (e.g. specialist or 
inpatient cohorts, specific dementia types) and the way in which comorbidity is measured [3-9]. The 
extent of multiple medication use (polypharmacy) in dementia has been little studied. To our 
knowledge, only one population-based study has examined polypharmacy, which reported that 
people with Alzheimer's disease took statistically significantly higher numbers of medication 
compared to controls when adjusted for gender and age (5.1 vs. 2.9) [10]. 
Comorbidity and polypharmacy are both associated with worsening effects on cognition, functional 
ability and survival of individuals with dementia [11, 12]. This paper examines a large population 
sample of people aged 65 years and over, examining prevalence of physical co-morbidity and 
polypharmacy in people with and without dementia. We have used similar methods to explore 
comorbidity and polypharmacy in schizophrenia [13] and bipolar disorder [14] in the same 
population dataset. 
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Methods 
Data for this cross sectional study was provided by the Primary Care Clinical Informatics Unit at the 
University of Aberdeen for all registered patients who were alive and permanently registered with 
314 general practices on March 31st 2007. The 1,751,841 people registered with these practices are 
a representative sample of approximately one-third of the Scottish population, and 291,169 people 
aged 65 years and over are included in this analysis. 
People were identified as having dementia based on recording at any point of a relevant Read Code 
(the standard clinical coding system in use in UK primary care) including Alzheimer's disease, 
vascular dementia, Lewy Body dementia, dementia associated with other conditions such as 
Parkinson's Disease, and unspecified dementia . The two outcomes examined were measures of 
physical co-morbidity and number of repeat prescriptions. Data on the presence of 32 chronic 
physical health conditions were extracted (see Table 1).  A more detailed explanation of how these 
conditions were selected and defined is available elsewhere[15]. 
Data on the number of drugs authorised for repeat prescription and issued to the patient in the 
previous 84 days was extracted. The count of number of repeat prescription drugs includes all 
pharmacologically active drugs, but excludes devices, dressings and topical preparations without 
significant systemic effects. Deprivation status was measured using the Carstairs’ deprivation score 
which is widely used in healthcare research and was grouped into quintiles [16]. Age was categorised 
into five year bands from age 65-69 years to age 95 years and over.  
Differences between individuals with dementia and all other individuals (controls) were calculated 
for age, deprivation status, number of physical conditions and number of repeat prescriptions as 
defined above.  T-tests were used to analyse differences between groups and one-way ANOVA for 
differences across age groups and deprivation quintiles. As with previous papers, to control for 
differences between the two populations in age, gender and deprivation levels, we generated 
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standardised prevalence rates by age group (65 to 69 years; 70 to 74; 75 to 79; 80 to 84; and 85 and 
older), gender and deprivation quintile using the direct method [17]. These age-gender standardised 
rates were then used to calculate odds ratio (ORs) and 95% confidence intervals in those with 
dementia compared with those without for the prevalence of all 32 physical conditions, as well as no 
physical condition, one physical condition, two physical conditions, three, four and five or more 
physical conditions.  Age-gender standardised rates were calculated in a similar fashion for the 
number of repeat prescriptions. All quoted odds ratios in the results are age-sex standardised. The 
NHS National Research Ethics Service had previously approved the use of these data for research 
purposes, therefore this study did not need individual ethical approval. 
Results 
There were 10,528 people with dementia recorded in the GP electronic medical record, 3.6% (95% CI 
3.5 to 3.7) of those aged 65 and over (Table 1).  People with dementia were more likely to be women 
(70.6% versus 56.7% of controls; p<0.001) and were on average older (mean age 82.6 years vs. 74.7 
years; p<0.001). Only 14.9% of people with dementia were aged between 65 and 74 compared to 
54.8% of those without, while 42.6% of people with dementia were 85 and over compared to 11.4% 
(difference 31.2%;p<0.001). No substantial or consistent differences were found by deprivation.  
Physical co-morbidity in people with dementia versus controls 
People with dementia had on average 2.9 physical conditions compared to 2.4 for controls (p<0.001) 
(Table 1). Only 8.7% of those with dementia had no physical condition compared to 15.9% of 
controls (OR 0.62, 95% CI 0.58 to 0.66) while 19% with dementia had five or more physical 
conditions compared to 13.4% of controls (OR 1.42, 95% CI 1.35 to 1.50).  
Table 2 shows that the most commonly diagnosed condition for individuals with dementia was 
hypertension with a prevalence rate of 43.2% followed by constipation (25.9%), coronary heart 
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disease (CHD) (22.8%), stroke (19.4%) and pain (16.0%). For each of the 32 individual physical 
conditions assessed, age-sex standardised prevalence was significantly higher for dementia for 16 
conditions, lower for three conditions and no difference was found for the remaining 13 conditions 
(table 2).  Relative prevalence was highest for dementia versus controls for Parkinson’s disease (OR 
4.32, 95% CI 3.84-4.29), epilepsy (OR 3.26, 95% CI 2.90-3.67) and constipation (OR 2.65, 95% CI 2.52-
2.79). The three physical conditions in which the prevalence for dementia patients was significantly 
lower following standardisation were cancer (OR 0.88, 95% CI 0.82 to 0.95), hypertension (OR 0.81, 
95% CI 0.78 to 0.85) and asthma (OR 0.73, 95% CI 0.67 to 0.80). 
Polypharmacy in people with dementia versus controls 
People with dementia were on average on more active repeat prescriptions (mean number of 
repeats 5.4 vs. 4.2; p<0.001). Table 3 shows that only 10.9% of those with dementia were not on a 
repeat prescription compared to 18.3% of controls (OR 0.54; 95% CI 0.51 to 0.58; p<0.001). Over half 
of those with dementia were on five or more repeat prescriptions with 43.2% on five to nine repeat 
prescriptions compared to 32.4% of controls  (OR 1.46; 95% CI 1.40 to 1.52; p<0.001) and 14% on ten 
or more compared to 8.4% of controls (OR 2.01; 95% CI 1.90 to 2.12; p<0.001). Apparent differences 
were reduced after standardising for number of physical conditions. For example, the odds ratios for 
those on five to nine repeat prescriptions fell to 1.23 (1.18-1.29) and 1.47 (1.38-1.58) for ten or 
more.  
Discussion 
Main Findings 
This study of a large, non-selected general practice population sample shows that older people with 
dementia had more physical co-morbidity and polypharmacy than those without dementia. Those 
with dementia were more likely to have five or more physical conditions (not including dementia) 
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and to be on five or more repeat prescriptions. The age-sex standardised prevalence of individual 
physical conditions was significantly higher in dementia for 16 conditions, lower for three conditions 
and not different from the controls for the remaining 13 conditions.  
Limitations 
One of the strengths of this study is the large sample size (291,691 community living people aged 65 
years and over), which is representative of the wider population in terms of age, sex and deprivation 
and avoids the biases that are inevitable in clinic or hospital based cohorts. However, the study relies 
on routine clinical recording of dementia diagnosis, which is known to be lower than expected, 
although recording in Scotland has historically been better than elsewhere in the UK [18]. Dementia 
diagnosis appeared to be under-recorded compared to the expected prevalence in the over 65s.  
Given known difficulties with early dementia identification and recording in general practice [19], 
this sample may therefore be more likely to describe co-morbidity among  "diagnosed" patients with 
moderate to severe dementia. Thus the data may under specify the comorbidity patterns present 
among patients with earlier stage disease or among undiagnosed patients in residential care, with 
potentially higher comorbidity burden. The extent and range of co-morbidity may also be 
underestimated due to dementia related difficulties with communication and symptom self-report. 
Comparison with related work 
Other studies have also shown high rates of physical comorbidity and medication use in people with 
dementia, [3-5, 9, 23] although not all studies find this, [6-8] and the current sample is more 
representative than many of those studied previously. Disease stage and the care setting from which 
patients are recruited are likely to influence the prevalence of and identification of physical 
conditions across different study populations [4, 6-8]. For co-morbidity these results broadly agree 
with the findings of the only other large routine heath dataset  published to date, which described 
administrative claims data and recorded higher comorbid conditions among people with dementia 
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than their matched controls [9]. The same authors note that even when illness burden is controlled 
for, the care costs of patients with dementia may be up to 34% higher than those of aged matched 
controls, with outpatient pharmaceuticals being the key driver of cost difference [20]. A recent 
Spanish primary care based study found increased rates of Parkinson's disease and cerebrovascular 
disease, consistent with this dataset,[21] but additionally reported higher rates of thyroid conditions, 
heart disease, retinal disorder and prostatic hypertrophy. This sample of 3,971 people with dementia 
was however, considerably smaller than the population reported here.  Other studies report 
variation in condition prevalence between populations with or without dementia, suggestive of 
additional moderating factors. In a cross-sectional study of seven US primary care centres by 
Schubert and colleagues, medical co-morbidity was equally common in people with and without 
dementia[6]. Lyketsos and colleagues, however, reported more comorbidity among people with 
cognitive impairment and no dementia and individuals with dementia compared to those without 
these conditions in a population based study [5]. Equivalent comorbidity was similarly found in an 
inpatient study comparing very old (mean age 85.2 years) people with and without cognitive 
impairment,[8] but this, like other inpatient studies, is unlikely to be representative of the whole 
population of older people with and without dementia [22]. Similar issues apply to studies in 
specialist clinics, such as an earlier report in 1988 examining outpatients with Alzheimer’s disease, 
which concluded that this patient group were healthier than those without dementia [7]. Bunn and 
colleagues review the dementia comorbidity literature with a focused exploration of disease 
prevalence in stroke, diabetes and visual impairment [23]. They note studies reporting both elevated 
and equivalent prevalence of stroke and diabetes relative to controls, suggestive of some data 
variability related to population selection and representativeness. 
This study found that polypharmacy is more common among people with dementia, even after age, 
gender and comorbidity adjustment, similar to other studies which have found polypharmacy to be 
common in people with dementia. A large Swedish dataset reported that 33.5% of patients were 
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receiving five or more regular medications [24]. In a study of nursing home residents with advanced 
cognitive impairment, 13.9% of the population were on ten or more regular prescribed medications 
[12]. Another study in Norway reported that participants with Alzheimer's Disease were treated with 
a significantly higher number of medications as compared to controls (5.1 vs. 2.9 respectively), even 
after adjustment for co-morbidity [10]. In particular, previous work using the same dataset as this 
analysis has shown that people with dementia are seventeen times more likely to be prescribed an 
antipsychotic and twice as likely to be prescribed an antidepressant or a hypnotic/anxiolytic than 
older people without dementia [25]. 
Relevance to practice and policy 
These findings have a number of implications for the development of policy and dementia care 
pathways. Both co-morbidity and polypharmacy may individually have a detrimental effect on 
outcomes of people with dementia. Research indicates that co-morbidity may have a direct negative 
effect on the clinical manifestation of dementia [12, 25-27] including the potential to increase rate of 
cognitive decline and accelerate functional decline, up to two years before patients without co-
morbidity [27, 28]. Polypharmacy has also been shown to be associated with negative outcomes in 
people with dementia. In the SHELTER study, in patients with severe dementia, polypharmacy 
(defined as 10 medications or more) was associated with increased mortality[12].  
Emergent evidence indicates that multidisciplinary treatment strategies may have the potential to 
reduce rates of antipsychotic prescription. Approaches that have been evaluated include timely 
screening of short term health conditions, systematic pain management protocols, and 
appropriately targeted psychosocial intervention [29]. Clodomiro and colleagues explore the 
possibility of applying risk benefit approaches to prescription according to factors such as frailty and 
multi-morbidity, highlighting in particular the incompatibility of anti-cholinergic treatments with 
many other medications commonly prescribed in elderly care settings [30]. 
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Conclusions 
This analysis, describing one of the largest population samples described to date, has shown high 
rates of physical comorbidity and polypharmacy in older people with dementia, which are both 
increased compared to the age-sex standardised control population. Given increasingly evidenced 
indications of the detrimental impact of comorbidity and polypharmacy, these findings highlight the 
need to re-evaluate and improve multidisciplinary integration of physical and mental health across a 
wide spectrum of care provision. Future research might usefully evaluate strategies for the active 
management of comorbidity and medication review to see whether it slows decline or improves 
function in people with dementia.  
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Tables and Captions 
Table 1. Age, gender, deprivation and number of conditions with confidence intervals and odds 
ratios shown 
 People with dementia 
N=10,528 
No. (%) unless stated 
People without dementia 
N=280,641 
No. (%) unless stated 
Difference 95% CI (p<t) 
Female 7428 (70.6) 159,028 (56.7) 13.9 (p<0.001) 
Mean age (SD) 82.6 (7.4) 74.7 (7.2) 7.9 (p<0.001) 
Age group    
65 to 69 579 (5.5) 83,023 (29.6) -24.1 (p<0.001) 
70 to 74 986 (9.4) 70,692 (25.2) -15.8 (p<0.001) 
75 to 79 1,832 (17.4) 56,369 (20.1) -2.7 (p<0.001) 
80 to 84 2,650 (25.2) 38,469 (13.7) 11.5 (p<0.001) 
85 to 89 2,575(24.5) 21,985(7.8) 16.6 (p<0.001) 
90 to 94 1,417 (13.5) 7,864 (2.8) 10.7 (p<0.001) 
95 and above 489 (4.6) 2,239 (0.8) 3.8 (p<0.001) 
Deprivation Quintile    
1 (least deprived) 2,130 (20.2) 52,978 (18.9) 1.3 (p<0.001) 
2 2,400 (22.8) 65,255 (23.3) -0.5 (p=0.27) 
3 2,459 (23.4) 64,634 (23.0) 0.4 (p=0.43) 
4 1,815 (17.2) 51,936 (18.5) -1.3 (p=0.01) 
5 (most deprived) 1,724 (16.4) 45,838 (16.3) 0.01 (p=0.98) 
   Odds ratio (95% CI) 
Directly standardised for 
age and sex 
No Physical 912 (8.7) 44,654 (15.9) 
0.62 (0.58 to 0.66) 
p<0.001 
One Physical 1,894 (18.0) 60,596 (21.6) 
0.83 (0.79 to 0.87) 
p<0.001 
Two  Physical 2,202 (20.9) 59,922 (21.4) 
0.92 (0.88 to 0.97) 
p=0.01 
Three Physical 2,010 (19.1) 46,638 (16.6) 
1.19 (1.14 to 1.25) 
p<0.001 
Four Physical 1,508 (14.3) 31,278 (11.2) 
1.20 (1.13 to 1.27) 
p<0.001 
Five or more Physical 2,005 (19.0) 37,553 (13.4) 
1.42 (1.35 to 1.50) 
p<0.001 
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Table 2 Prevalence and odds ratios for individual conditions, standardised by age and gender 
Individual Conditions People with 
dementia 
No.(%) 
N=10,528 
People without 
dementia 
No. (%) 
N=280,641 
Odds ratio (95% CI) 
Directly standardised for age 
and sex 
Parkinson’s Disease/Parkinsonism 310 (2.9) 2,022 (0.7) 4.32 (3.84 to 4.29) p<0.001 
Epilepsy 226 (2.1) 2,704 (1.0) 3.26 (2.90 to 3.67) p<0.001 
Constipation 2,728 (25.9) 22,788 (8.1) 2.65 (2.52 to 2.79) p<0.001 
Inflammatory arthritis, connective 
tissue disorders and gout 
1,433 (13.6) 27,442 (9.8) 2.23 (2.12 to 2.34) p<0.001 
Stroke/TIA 2,038 (19.4) 25,634 (9.1) 2.13 (2.02 to 2.13) p<0.001 
Multiple sclerosis 23 (0.2) 702 (0.3) 2.07 (1.57 to 2.74) p<0.001 
Liver Disease 25 (0.2) 769 (0.3) 1.80 (1.35 to 2.39) p<0.001 
Viral Hepatitis 2 (0.0) 46 (0.0) 1.77 (0.55 to 5.72) p=0.33 
Psoriasis or eczema 131 (1.2) 2,882 (1.0) 1.69 (1.46 to 1.97) p<0.001 
Inflammatory bowel disease 98 (0.9) 2,659 (1.0) 1.50 (1.27 to 1.77) ) p<0.001 
Blindness or low vision 418 (4.0) 4,930 (1.8) 1.48 (1.31 to 1.68) p<0.001 
Pain 1,684 (16.0) 53,590 (19.1) 1.16 (1.10 to 1.21) p<0.001 
Atrial fibrillation 1,124 (10.7) 18,583 (6.6) 1.13 (1.05 to 1.22) p=0.01 
Thyroid Disorders 1,526 (14.5) 30,955 (11.0) 1.14 (1.07 to 1.21) p<0.001 
Diabetes 1,397 (13.3) 37,347 (13.3) 1.14 (1.08 to 1.21) p<0.001 
Hearing Loss 1,454 (13.8) 26,122 (9.3) 1.11 (1.04 to 1.18) p=0.01 
Peripheral vascular disease 547 (5.2) 14,108 (5.0) 1.07 (0.98 to 1.17) p=0.10 
CHD 2,399 (22.8) 57,303 (20.4) 1.06 (1.01 to 1.11) p=0.01 
Prostate 357 (3.4) 10,069 (3.6) 1.06 (0.96 to 1.17) p=0.23 
Diverticular  1,196 (11.4) 23,521 (8.4) 1.04 (0.97 to 1.11) p=0.21 
Bronchiectasis 51 (0.5) 1,560 (0.6) 1.04 (0.80 to 1.35) p=0.72 
COPD 976 (9.3) 28,562 (10.2) 1.03 (0.96 to 1.10) p=0.33 
Chronic kidney disease 1,304 (12.4) 27,108 (9.7) 1.03 (0.96 to 1.10) p=0.34 
Irritable bowel syndrome 361 (3.4) 11,332 (4.0) 0.99 (0.89 to 1.09) p=0.98 
Glaucoma 590 (5.6) 11,127 (4.0) 0.99 (0.90 to 1.10 ) p=0.99 
Heart Failure 727 (6.9) 14,041 (5.0) 0.98 (0.89 to 1.07) p=0.68 
Dyspepsia 1,225 (11.6) 32,352 (11.5) 0.96 (0.90 to 1.02) p=0.09 
Chronic sinusitis 55 (0.5) 2,097 (0.8) 0.89 (0.70 to 1.13) p=0.36 
Any cancer last 5 years 863 (8.2) 23,353 (8.3) 0.88 (0.82 to 0.95) p<0.001 
Migraine 20 (0.2) 1,203 (0.4) 0.83 (0.59 to 1.15) p=0.27 
Hypertension 4,548 (43.2) 131,853 (47.0) 0.81 (0.78 to 0.85) p<0.001 
Asthma 363 (3.5) 18,639 (6.6) 0.73 (0.67 to 0.80) p<0.001 
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Table 3 Prevalence and odds ratios for repeat prescribing, standardised by age  gender and 
number of physical conditions 
 
Number  of 
active repeat 
medications* 
People with 
dementia 
No. (%) 
N=10,528 
People 
without 
dementia 
No. (%) 
N=280,641 
Odds ratio (95% CI) 
Directly 
standardised for 
age and sex 
Odds ratio (95% CI)  
Directly standardised 
for age, sex, and 
number of physical 
conditions 
No Repeats 1,145 (10.9) 
51,209 
(18.3) 
0.54 (0.51 to 0.58) 
p<0.001 
0.74 (0.69 to 
0.74)p<0.001 
One Repeats 542 (5.2) 25,345 (9.0) 
0.59 (0.54 to 0.64) 
p<0.001 
0.73 (0.67 to 
0.80)p<0.001 
Two  Repeats 759 (7.2) 
29,477 
(10.5) 
0.77 (0.71 to 0.82) 
p<0.001 
0.77 (0.71 to 0.83) 
p<0.001 
Three Repeats 971 (9.2) 
30,431 
(10.8) 
0.79 (0.74 to 0.85) 
p<0.001 
0.87 (0.82 to 0.93) 
p<0.001 
Four repeats 1,098 (10.4) 
29,782 
(10.6) 
0.88 (0.82 to 0.94) 
p<0.001 
0.94 (0.88 to 
1.01)p=0.10 
Five to nine 
repeats 
4,544 (43.2) 
90,896 
(32.4) 
1.46 (1.40 to 1.52) 
p<0.001 
1.23 (1.18 to 
1.29)p<0.001 
Ten or more 
repeats 
1,469 (14.0) 23,501 (8.4) 
2.01 (1.90 to 2.12) 
p<0.001 
1.47 (1.38 to 
1.58)p<0.001 
* Authorised for repeat issue without a consultation and issued in the last 84 days 
 
